Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Affirm Holdings, Inc. stock logo
AFRM
Affirm
$32.08
-2.1%
$35.71
$8.80
$52.48
$9.84B3.579.46 million shs3.91 million shs
Arch Resources, Inc. stock logo
ARCH
Arch Resources
$159.11
+1.5%
$164.30
$102.42
$187.60
$2.90B0.68471,724 shs367,790 shs
Moderna, Inc. stock logo
MRNA
Moderna
$108.85
+0.9%
$101.39
$62.55
$142.79
$41.68B1.624.12 million shs3.41 million shs
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Affirm Holdings, Inc. stock logo
AFRM
Affirm
+2.49%+5.95%-9.10%-19.09%+211.11%
Arch Resources, Inc. stock logo
ARCH
Arch Resources
-2.79%-5.47%-3.59%-13.62%+24.31%
Moderna, Inc. stock logo
MRNA
Moderna
+3.28%+3.95%+2.33%+6.71%-21.90%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Affirm Holdings, Inc. stock logo
AFRM
Affirm
1.0624 of 5 stars
1.93.00.00.01.73.30.6
Arch Resources, Inc. stock logo
ARCH
Arch Resources
2.7555 of 5 stars
2.31.01.70.01.13.33.1
Moderna, Inc. stock logo
MRNA
Moderna
4.0601 of 5 stars
3.12.00.04.62.43.30.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Affirm Holdings, Inc. stock logo
AFRM
Affirm
1.83
Reduce$27.86-13.15% Downside
Arch Resources, Inc. stock logo
ARCH
Arch Resources
2.50
Moderate Buy$177.0011.24% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.24
Hold$126.4916.20% Upside

Current Analyst Ratings

Latest ARCH, MRNA, and AFRM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/23/2024
Affirm Holdings, Inc. stock logo
AFRM
Affirm
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral
4/23/2024
Affirm Holdings, Inc. stock logo
AFRM
Affirm
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold
4/22/2024
Arch Resources, Inc. stock logo
ARCH
Arch Resources
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$180.00
4/18/2024
Arch Resources, Inc. stock logo
ARCH
Arch Resources
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$185.00 ➝ $170.00
4/16/2024
Affirm Holdings, Inc. stock logo
AFRM
Affirm
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$50.00 ➝ $41.00
4/15/2024
Arch Resources, Inc. stock logo
ARCH
Arch Resources
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$198.00 ➝ $193.00
4/11/2024
Arch Resources, Inc. stock logo
ARCH
Arch Resources
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$160.00 ➝ $185.00
4/11/2024
Moderna, Inc. stock logo
MRNA
Moderna
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold
4/10/2024
Arch Resources, Inc. stock logo
ARCH
Arch Resources
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Market Perform$180.00 ➝ $165.00
4/9/2024
Moderna, Inc. stock logo
MRNA
Moderna
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$125.00
4/3/2024
Affirm Holdings, Inc. stock logo
AFRM
Affirm
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageHold
(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Affirm Holdings, Inc. stock logo
AFRM
Affirm
$1.59B6.20N/AN/A$8.54 per share3.76
Arch Resources, Inc. stock logo
ARCH
Arch Resources
$3.15B0.92$34.00 per share4.68$80.54 per share1.98
Moderna, Inc. stock logo
MRNA
Moderna
$6.85B6.09N/AN/A$36.33 per share3.00

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Affirm Holdings, Inc. stock logo
AFRM
Affirm
-$985.34M-$2.49N/AN/AN/A-39.19%-25.10%-7.76%5/8/2024 (Confirmed)
Arch Resources, Inc. stock logo
ARCH
Arch Resources
$464.04M$24.046.628.09N/A14.75%32.20%19.20%4/25/2024 (Confirmed)
Moderna, Inc. stock logo
MRNA
Moderna
-$4.71B-$12.41N/AN/AN/A-68.84%-10.23%-7.70%5/2/2024 (Confirmed)

Latest ARCH, MRNA, and AFRM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2024N/A
Affirm Holdings, Inc. stock logo
AFRM
Affirm
-$0.70N/A+$0.70N/AN/AN/A  
5/2/2024N/A
Moderna, Inc. stock logo
MRNA
Moderna
-$3.36N/A+$3.36N/AN/AN/A  
4/25/2024N/A
Arch Resources, Inc. stock logo
ARCH
Arch Resources
$2.79$3.49+$0.70N/AN/AN/A  
2/22/2024Q4 2023
Moderna, Inc. stock logo
MRNA
Moderna
-$0.78$0.55+$1.33$0.55$2.53 billion$2.80 billion    
2/15/2024Q4 23
Arch Resources, Inc. stock logo
ARCH
Arch Resources
$6.90$6.07-$0.83$6.07$704.53 million$774.00 million    
2/8/2024Q2 2024
Affirm Holdings, Inc. stock logo
AFRM
Affirm
-$0.28-$0.20+$0.08$0.14$523.92 million$591.11 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Affirm Holdings, Inc. stock logo
AFRM
Affirm
N/AN/AN/AN/AN/A
Arch Resources, Inc. stock logo
ARCH
Arch Resources
$1.000.63%+25.99%4.16%N/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A

Latest ARCH, MRNA, and AFRM Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/15/2024
Arch Resources, Inc. stock logo
ARCH
Arch Resources
Quarterly$0.250.6%2/28/20242/29/20243/15/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Affirm Holdings, Inc. stock logo
AFRM
Affirm
2.35
11.49
11.49
Arch Resources, Inc. stock logo
ARCH
Arch Resources
0.07
2.49
1.83
Moderna, Inc. stock logo
MRNA
Moderna
0.04
3.42
3.36

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Affirm Holdings, Inc. stock logo
AFRM
Affirm
69.29%
Arch Resources, Inc. stock logo
ARCH
Arch Resources
88.14%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%

Insider Ownership

CompanyInsider Ownership
Affirm Holdings, Inc. stock logo
AFRM
Affirm
13.05%
Arch Resources, Inc. stock logo
ARCH
Arch Resources
5.90%
Moderna, Inc. stock logo
MRNA
Moderna
15.20%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Affirm Holdings, Inc. stock logo
AFRM
Affirm
2,171306.87 million266.83 millionOptionable
Arch Resources, Inc. stock logo
ARCH
Arch Resources
3,40018.25 million17.17 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
5,600382.88 million324.68 millionOptionable

ARCH, MRNA, and AFRM Headlines

SourceHeadline
Moderna partners with OpenAI to supercharge mRNA research with genAIModerna partners with OpenAI to supercharge mRNA research with genAI
mmm-online.com - April 24 at 5:24 PM
Moderna Stock Jumps On Collaboration With OpenAI: Whats Going On?Moderna Stock Jumps On Collaboration With OpenAI: What's Going On?
msn.com - April 24 at 12:24 PM
Moderna and OpenAI in pact to fast-track drug developmentModerna and OpenAI in pact to fast-track drug development
msn.com - April 24 at 12:24 PM
Moderna and OpenAI Collaborate To Advance mRNA MedicineModerna and OpenAI Collaborate To Advance mRNA Medicine
accesswire.com - April 24 at 8:00 AM
Pfizer and BioNTech commence legal action against Moderna in UK courtPfizer and BioNTech commence legal action against Moderna in UK court
pharmaceutical-technology.com - April 24 at 7:23 AM
Handelsbanken Fonder AB Has $11.52 Million Holdings in Moderna, Inc. (NASDAQ:MRNA)Handelsbanken Fonder AB Has $11.52 Million Holdings in Moderna, Inc. (NASDAQ:MRNA)
marketbeat.com - April 24 at 6:49 AM
Moderna enters contract with Brazil to supply 12.5 million Covid-19 vaccines as part of national vaccination campaignModerna enters contract with Brazil to supply 12.5 million Covid-19 vaccines as part of national vaccination campaign
pharmabiz.com - April 24 at 2:22 AM
South Dakota Investment Council Acquires 44,779 Shares of Moderna, Inc. (NASDAQ:MRNA)South Dakota Investment Council Acquires 44,779 Shares of Moderna, Inc. (NASDAQ:MRNA)
marketbeat.com - April 23 at 9:10 PM
Moderna Faces Pfizer, BioNTech in London Patent Battle over Covid-19 Vaccines In Legal ShowdownModerna Faces Pfizer, BioNTech in London Patent Battle over Covid-19 Vaccines In Legal Showdown
msn.com - April 23 at 4:22 PM
Moderna Investors Should Beware Patent-Dispute FalloutModerna Investors Should Beware Patent-Dispute Fallout
seekingalpha.com - April 23 at 2:40 PM
Moderna, Pfizer/BioNTech set for UK court clash over COVID jab patentsModerna, Pfizer/BioNTech set for UK court clash over COVID jab patents
medicalxpress.com - April 23 at 11:21 AM
Moderna gets grant for vaccine composition for varicella zoster virusModerna gets grant for vaccine composition for varicella zoster virus
pharmaceutical-technology.com - April 23 at 11:21 AM
This may hurt: English High Court set for Moderna and Pfizer/BioNTech Covid battle starting todayThis may hurt: English High Court set for Moderna and Pfizer/BioNTech Covid battle starting today
msn.com - April 23 at 11:21 AM
Pfizer vs Moderna battle over COVID vaccine patents begins in UKPfizer vs Moderna battle over COVID vaccine patents begins in UK
reuters.com - April 23 at 7:21 AM
Moderna halts planned vaccine plant in KenyaModerna halts planned vaccine plant in Kenya
independent.co.ug - April 22 at 6:53 PM
Cwm LLC Has $11.77 Million Holdings in Moderna, Inc. (NASDAQ:MRNA)Cwm LLC Has $11.77 Million Holdings in Moderna, Inc. (NASDAQ:MRNA)
marketbeat.com - April 22 at 8:41 AM
Moderna Announces Contract with Brazil to Supply 12.5 million COVID-19 Vaccines as Part of National Vaccination CampaignModerna Announces Contract with Brazil to Supply 12.5 million COVID-19 Vaccines as Part of National Vaccination Campaign
accesswire.com - April 22 at 7:00 AM
Covid vaccine makers to clash in London over mRNA patent disputeCovid vaccine makers to clash in London over mRNA patent dispute
ft.com - April 22 at 12:45 AM
Noubar Afeyan Sells 15,000 Shares of Moderna, Inc. (NASDAQ:MRNA) StockNoubar Afeyan Sells 15,000 Shares of Moderna, Inc. (NASDAQ:MRNA) Stock
insidertrades.com - April 21 at 4:24 AM
Moderna stock traded in the red for the eighth straight dayModerna stock traded in the red for the eighth straight day
seekingalpha.com - April 20 at 7:07 PM
Moderna, Inc. (NASDAQ:MRNA) is APEIRON CAPITAL Ltds 7th Largest PositionModerna, Inc. (NASDAQ:MRNA) is APEIRON CAPITAL Ltd's 7th Largest Position
marketbeat.com - April 20 at 4:23 PM
Fact Check: mRNA Jabs Have Allegedly Caused a 14,000% Increase in Turbo Cancer. Heres What We FoundFact Check: mRNA Jabs Have Allegedly Caused a '14,000% Increase in Turbo Cancer.' Here's What We Found
news.yahoo.com - April 20 at 2:07 PM
Moderna, Inc. (NASDAQ:MRNA) Director Sells $1,550,700.00 in StockModerna, Inc. (NASDAQ:MRNA) Director Sells $1,550,700.00 in Stock
insidertrades.com - April 20 at 7:12 AM
CDC Said mRNA Jabs Have Caused a 14,000% Increase in Turbo Cancer?CDC Said mRNA Jabs Have Caused a '14,000% Increase in Turbo Cancer'?
msn.com - April 20 at 12:46 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Affirm logo

Affirm

NASDAQ:AFRM
Affirm Holdings, Inc. operates a platform for digital and mobile-first commerce in the United States, Canada, and internationally. The company's platform includes point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. Its commerce platform, agreements with originating banks, and capital markets partners enables consumers to pay for a purchase over time with terms ranging up to 60 months. The company has active merchants covering small businesses, large enterprises, direct-to-consumer brands, brick-and-mortar stores, and companies with an omni-channel presence. Its merchants represent a range of industries, including sporting goods and outdoors, furniture and homewares, travel and ticketing, apparel, accessories, consumer electronics, and jewelry. Affirm Holdings, Inc. was founded in 2012 and is headquartered in San Francisco, California.
Arch Resources logo

Arch Resources

NYSE:ARCH
Arch Resources, Inc. engages in the production and sale of metallurgical products. It operates in two segments, Metallurgical and Thermal. The company operates active mines. It owned or controlled primarily through long-term leases of coal land in Ohio, Maryland, Virginia, West Virginia, Wyoming, Kentucky, Montana, Pennsylvania, Colorado, and Illinois; and smaller parcels of property in Alabama, Indiana, Washington, Arkansas, California, Utah, and Texas. The company sells its products to utility, industrial, and steel producers in the United States and internationally. Arch Resources, Inc. was incorporated in 1969 and is headquartered in Saint Louis, Missouri.
Moderna logo

Moderna

NASDAQ:MRNA
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.